
    
      Patients, age 65 to 90, with Neovascular Age-Related Macular Degeneration who present for
      treatment with intravitreal ranibizumab or aflibercept will be selected in this study. 300
      subjects from one site in the United States will be enrolled.

      Inclusion Criteria:

        -  Ability to provide written informed consent and comply with study

        -  Age 65-90 years

        -  Diagnosis of Neovascular Age-Related Macular Degeneration who present for treatment with
           intravitreal ranibizumab or aflibercept

      Exclusion Criteria:

        -  Previous intraocular inflammation

        -  Treatment with systemic anti-inflammatory agents

        -  Known systemic autoimmune diseases

        -  Treatment with intraocular steroids in the past 3 months

        -  History of intraocular surgery in the past 3 months

        -  Age greater than 90 years

        -  Patients who were switched between either therapies in the past 3 months
    
  